Screening of single nucleotide polymorphism in matrix metalloproteinase‐2 ( MMP2 ) and tetraspanin CD63 genes in Chlamydia trachomatis ‐infected tubal ectopic pregnancy patients
International Journal of Gynecology & Obstetrics · 2024
DOI: 10.1002/ijgo.15547 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Gynecology & Obstetrics, 2024. Verfasst von Shipra Pant und 5 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Microbiology Laboratory, ICMR-National Institute of Pathology, Sriramachari Bhawan, Safdarjung Hospital Campus, New Delhi, India. Hauptthemen laut MEDLINE: Chlamydia Infections, Chlamydia trachomatis, Polymorphism, Single Nucleotide, Matrix Metalloproteinase 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Objective
Tubal ectopic pregnancy (EP) is a leading cause of maternal morbidity and mortality. Studies have suggested that infection‐induced inflammatory responses are major risk factors for EP. The aim of the present study was to find an association between MMP2 and CD63 gene variants and risk of EP during Chlamydia trachomatis infection in an Indian population.
Methods
Fallopian tube samples of 120 EP and 120 tubal ligation women were collected. C. trachomatis was detected by PCR. The genotyping of MMP2 (rs17859882 G/T, rs7201A/C) and CD63(rs2231464 C/T, rs376086542 A/G) gene variants was done by qualitative real‐time PCR using allelic discrimination method (VIC‐ and FAM‐labeled).
Results
The frequency of GG or GT genotype of MMP2 G/T polymorphism (rs17859882) was 66.6% in infected EP and 36.7% in uninfected EP and 22% in tubal ligation controls ( P < 0.0001), while the frequency of AC or CC genotype of MMP2 A/C polymorphism (rs7201) was 66.6% in infected EP and 20.6% in uninfected EP and 13.5% in tubal ligation controls ( P < 0.0001). The frequency of CT or TT genotype of CD63 C/T polymorphism (rs2231464) was 74% in infected EP and 21.8% in uninfected EP and 11.8% tubal ligation controls ( P < 0.0001), while the frequency of AG or GG genotype of CD63 A/G polymorphism (rs376086542) was 48.1% in infected EP and 41.3% in uninfected EP and 18.6% tubal ligation controls ( P < 0.0001).
Conclusions
The present study revealed a strong association between the presence of gene variants MMP2 (rs17859882 G/T, rs7201A/C) and CD63 (rs2231464 C/T, rs376086542 A/G) and risk of tubal EP during C. trachomatis infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Microbiology Laboratory, ICMR-National Institute of Pathology, Sriramachari Bhawan, Safdarjung Hospital Campus, New Delhi, India.
- Department of Obstetrics and Gynecology, Vardhman Mahavir Medical College (VMMC) and Safdarjung Hospital, New Delhi, India.
- Pathology Laboratory, ICMR-National Institute of Pathology, Sriramachari Bhawan, Safdarjung Hospital Campus, New Delhi, India.
ORCID-Profile: Sangita Rastogi
Zitieren
APA
Pant, S., Bhati, T., Dimri, A., Arora, R., Siraj, F., & Rastogi, S. (2024). Screening of single nucleotide polymorphism in matrix metalloproteinase‐2 ( MMP2 ) and tetraspanin CD63 genes in Chlamydia trachomatis ‐infected tubal ectopic pregnancy patients. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.15547
Vancouver
Pant S, Bhati T, Dimri A, Arora R, Siraj F, Rastogi S. Screening of single nucleotide polymorphism in matrix metalloproteinase‐2 ( MMP2 ) and tetraspanin CD63 genes in Chlamydia trachomatis ‐infected tubal ectopic pregnancy patients. International Journal of Gynecology & Obstetrics. 2024. doi:10.1002/ijgo.15547
BibTeX
@article{Pant2024,
author = {Pant, Shipra and Bhati, Tanu and Dimri, Astha and Arora, Renu and Siraj, Fouzia and Rastogi, Sangita},
title = {Screening of single nucleotide polymorphism in matrix metalloproteinase‐2 ( MMP2 ) and tetraspanin CD63 genes in Chlamydia trachomatis ‐infected tubal ectopic pregnancy patients},
journal = {International Journal of Gynecology & Obstetrics},
year = {2024},
doi = {10.1002/ijgo.15547}
}
EUVIMED